Core Insights - Syra Health Corp. reported a decline in revenue for Q3 2025, primarily due to federal spending cuts impacting state and county government budgets, with revenue falling to $1.7 million from $2.3 million in Q3 2024 [5][7] - The Population Health business unit experienced significant growth of 96% year-over-year, indicating strong market demand for its solutions [3][8] - The company improved its gross margin by 300 basis points to 33% and reduced its net loss by 46% through cost management and operational efficiency [3][7] Financial Performance - Q3 2025 revenue was $1.7 million, down from $2.3 million in Q3 2024, largely due to federal budget cuts [5][14] - Population Health segment revenue reached $1,280,011, up from $652,298 in Q3 2024, driven by upselling to state health departments and private sector customers [8][14] - Gross margin improved to 33% in Q3 2025 from 30% in Q3 2024, attributed to a strategic focus on higher-margin business units [8][14] - Net loss decreased to ($225,902) in Q3 2025 from ($417,535) in Q3 2024, reflecting improved operational efficiency [7][14] Cost Management - Total operating expenses for Q3 2025 were $786,712, a 28% decline from $1,097,208 in the previous year, due to disciplined cost management [9][14] - Salaries and benefits decreased by 43% to $336,390, resulting from workforce optimization efforts [9][14] - Selling, general, and administrative expenses fell by 12% to $252,384 as part of overhead reduction initiatives [11][14] Strategic Focus - The company is refining its strategy to concentrate on its successful Population Health solutions, which is contributing to growth in its sales pipeline [4][5] - Syra Health's focus on targeted upselling and expansion into the private sector is expected to enhance its market position as federal budget clarity improves [4][5] Cash Position - As of September 30, 2025, Syra Health had cash and cash equivalents of $2.0 million and no long-term debt [11][12] - The company continues to manage its cash flow effectively, with a net cash used in operating activities of ($158,554) for the quarter [15]

Financial Data and Key Metrics Changes - Total revenue for 2024 was $8 million, reflecting a 45% growth compared to $5.5 million in 2023 [30] - Gross profit margin decreased to 20.7% in 2024 from 25.6% in 2023, primarily due to timing differences in revenue recognition and low-margin contracts being phased out [9][38] - Net loss for 2024 was $3.7 million, an increase from $2.9 million in 2023, but the net loss for Q4 2024 improved to $504,000 from $995,000 in Q4 2023 [44] Business Line Data and Key Metrics Changes - Population Health revenues were $1.7 million in 2024, more than double the $715,000 in 2023, with a Q4 revenue of $418,000, a 285% increase year-over-year [32][33] - Healthcare Workforce revenues increased to $5.9 million in 2024 from $4.3 million in 2023, with Q4 revenue reaching $1.5 million, a 17% growth [34] - Health Education business unit saw revenues grow to $40,000 in 2024 from $12,000 in 2023, with expectations for continued growth [36] Market Data and Key Metrics Changes - Non-Healthcare Workforce revenues accounted for 26% of total revenues in 2024, up from 23% in 2023, indicating a strategic shift towards higher-margin revenue streams [15] - The company has potential RFP submissions equating to $80 million in multiyear contract value, indicating strong market demand [12] Company Strategy and Development Direction - The company is focused on diversifying revenue streams and enhancing operational efficiencies to improve margins and profitability [11][14] - Strategic priorities include expanding the sales pipeline, targeting higher-margin revenues, and investing in innovative technology products [14][50] - The Syrenity App is a key product aimed at capturing growth in the mental and behavioral health markets, with plans for international expansion [13][18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about improving margins and profitability, driven by a focus on high-margin offerings and operational efficiencies [11][46] - The company anticipates low-double digit percentage revenue growth for 2025, supported by strong trends exiting 2024 [46] Other Important Information - The company has implemented cost-cutting measures resulting in a 39% reduction in operating expenses in Q4 2024 compared to Q4 2023 [17][40] - The Syrenity App has shown positive preliminary results in clinical studies, indicating its potential effectiveness in improving mental health outcomes [20] Q&A Session Summary Question: What was the rationale for filing a mixed shelf for up to $75 million? - The shelf allows the company to streamline capital raise tasks and provides flexibility for acquisitions and strategic initiatives [54] Question: How will the company protect itself from the risk of delisting due to non-compliance? - The company is in compliance with Nasdaq Listing standards, maintaining stockholder equity above the required minimum [57] Question: How does Syra plan to address the minimum bid price issue? - The company is exploring options to regain compliance without reverse stock splits, focusing on strengthening fundamentals [59] Question: Can you tell me about the sales of Syrenity? - The company is marketing Syrenity to various sectors, with an expanding addressable market and expectations for recurring revenue growth [61] Question: Any updates on the Federal government contracts announced in early 2024? - The company is actively bidding on task orders under the Federal contracts and will provide updates as they materialize [64]